Merck Keytruda Price Catalyst: Adjuvant OK
Decision brief
Answer first · skim in under a minute
Merck keytruda price is a relevant watch item after the FDA’s January 26, 2023 approval of pembrolizumab for adjuvant treatment of resected early-stage NSCLC. The catalyst expands Keytruda’s lung cancer footprint and gives BD teams, investors, and analysts a dated regulatory milestone to track.
FDA adjuvant NSCLC approval turned Keytruda into an earlier-line lung cancer franchise event. For teams tracking Merck Keytruda price and volume, the catalyst is KEYNOTE-091 disease-free survival after surgery and platinum chemotherapy.
Contents12 sections
Key Takeaways
- January 26, 2023 FDA approval added adjuvant Keytruda for stage IB (T2a >=4 cm)-IIIA NSCLC after chemo.
- Chemo-treated KEYNOTE-091 patients: median DFS 58.7 vs 34.9 months (HR 0.73).
- Up to 1 year of adjuvant dosing is a durable volume catalyst even if Merck Keytruda price is flat.
- No-chemo exploratory subgroup did not show benefit; keep models label-faithful.
What did FDA approve for adjuvant Keytruda in NSCLC?
On January 26, 2023, the FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a >=4 cm), II, or IIIA NSCLC.
Dosing in KEYNOTE-091 was pembrolizumab 200 mg or placebo every 3 weeks for up to 1 year. Of 1,177 randomized patients, 1,010 (86%) received adjuvant platinum chemotherapy after complete resection.
What did KEYNOTE-091 show on disease-free survival?
For patients who received adjuvant chemotherapy, median DFS was 58.7 months with pembrolizumab versus 34.9 months with placebo (hazard ratio 0.73; 95% CI 0.60-0.89).
- Trial ID: NCT02504372
- Nearly 24-month median DFS improvement in the chemo-treated group
- No PD-L1 selection required on the adjuvant label
In an exploratory subgroup of 167 patients who did not receive adjuvant chemotherapy, the DFS hazard ratio was 1.25 (95% CI 0.76-2.05). That subgroup is not a win.
How does Merck Keytruda price interact with this catalyst?
A catalyst can be volume-led. Adjuvant adoption increases treated patient-months; net price still depends on contracting, 340B, and Medicare negotiation.
Do not cite an unsourced WAC. FDA and Merck pages confirm clinical facts, not list price.
What risks could blunt the catalyst?
Immune toxicities, including pneumonitis and rare fatal myocarditis, can interrupt adjuvant courses. Competing perioperative regimens may shrink the addressable pool.
Exploratory DFS HR 1.25 without adjuvant chemo warns against over-broad marketing claims.
Which safety signals did FDA highlight?
FDA noted adverse reactions generally similar to single-agent Keytruda in NSCLC, with hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%) called out. Two fatal myocarditis events occurred.
Immune-related toxicity management affects real-world completion of the up-to-one-year adjuvant course and therefore realized volume.
What remains unproven after the 2023 label?
Overall survival maturity in routine care, competing perioperative regimens, and Medicare price-negotiation outcomes are not settled by the approval memo alone.
Public FDA pages do not publish a Keytruda WAC. Delete unsourced Merck Keytruda price dollar figures rather than inventing them.
How should teams document claims for compliance?
Copy efficacy numbers only from FDA pages or peer-reviewed publications. When an IR release rounds a hazard ratio, prefer the FDA confidence interval in diligence decks.
Keep a source table with URL, access date, and the exact sentence supporting each percentage. That habit prevents AI citation drift and auditor failures.
What operational questions follow the clinical catalyst?
Ask whether infusion chairs, biomarker testing, and adverse-event pathways exist before modeling peak share. Clinical wins stall when operations cannot deliver the labeled regimen.
For pricing keywords, separate list price, net price, and policy risk. Invented WAC figures are worse than omitting price entirely.
Related NovaPharma coverage
- FDA Approves Keytruda Adjuvant NSCLC (Merck)
- Medicare price rule, Keytruda and Opdivo subcutaneous launches
- Merck Harpoon Therapeutics acquisition oncology pipeline
Frequently Asked Questions
When did FDA approve Keytruda for adjuvant NSCLC?
On January 26, 2023, FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a >=4 cm), II, or IIIA NSCLC.
What trial supported adjuvant Keytruda in NSCLC?
KEYNOTE-091 (NCT02504372) randomized 1,177 patients. Among the 1,010 who received adjuvant platinum chemotherapy, median DFS was 58.7 months with pembrolizumab versus 34.9 months with placebo (HR 0.73; 95% CI 0.60-0.89).
Does adjuvant Keytruda require PD-L1 positivity?
FDA approval text does not require PD-L1 selection for this adjuvant indication. The chemotherapy-treated subgroup benefit was reported regardless of PD-L1 expression.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pembrolizumab.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…